124 related articles for article (PubMed ID: 12486411)
1. New options in lipid management--can we extend the benefits of current therapy? Introduction.
Gotto AM; Paoletti R
Am Heart J; 2002 Dec; 144(6 Suppl):S19-20. PubMed ID: 12486411
[No Abstract] [Full Text] [Related]
2. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
3. Choice of lipid-regulating drugs.
Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632
[No Abstract] [Full Text] [Related]
4. Risk reduction strategies in coronary artery disease.
Gibson TM; Ratts T
J La State Med Soc; 2001 Jun; 153(6):312-9. PubMed ID: 11480382
[TBL] [Abstract][Full Text] [Related]
5. Current drug treatments for lipid management.
Stone NJ
Manag Care; 2002 Sep; 11(9 Suppl):4-9. PubMed ID: 12369341
[No Abstract] [Full Text] [Related]
6. Rationale for aggressive lipid lowering: evidence from clinical trials.
Farmer JA
Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477
[No Abstract] [Full Text] [Related]
7. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
8. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Kastelein JJ
Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
[TBL] [Abstract][Full Text] [Related]
9. [Hydroxymethylglutaryl coenzyme A reductase inhibitors].
Schuff-Werner P
Internist (Berl); 1994 Mar; 35(3):288-94; discussion 295. PubMed ID: 8175295
[No Abstract] [Full Text] [Related]
10. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
[No Abstract] [Full Text] [Related]
11. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
12. [Indications for decreasing lipid values. Patients with healthy hearts with low HDL clearly profit].
MMW Fortschr Med; 2000 Nov; 142(48):68. PubMed ID: 11138292
[No Abstract] [Full Text] [Related]
13. Statins. Cholesterol lowering and beyond.
Mayo Clin Womens Healthsource; 2006 Jun; 10(6):1-2. PubMed ID: 16675916
[No Abstract] [Full Text] [Related]
14. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
Stone NJ; Bilek S; Rosenbaum S
Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk of coronary heart disease via lipid reduction.
Spratt KA
J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of dyslipidemia in clinical practice].
Paragh G; Harangi M
Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
[TBL] [Abstract][Full Text] [Related]
17. Intensive lipid lowering with atorvastatin in coronary disease.
Modest GA
N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003833
[No Abstract] [Full Text] [Related]
18. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
19. [What other effects do statins have except their effect on lipids?].
Tikkanen MJ
Duodecim; 1998; 114(13):1299-301. PubMed ID: 11552256
[No Abstract] [Full Text] [Related]
20. Low HDL-C: a secondary target of dyslipidemia therapy.
Rosenson RS
Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
